Literature DB >> 11760927

Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).

R L Deamer1, D R Wilson, D S Clark, J G Prichard.   

Abstract

A patient undergoing management of heroin dependency with high dosages of the long-acting methadone derivative, levomethadyl acetate HCl (LAAM; ORLAAM) developed a prolonged QTc interval and polymorphic QRS complexes on EKG consistent with torsades de pointes (TdP). The patient was taking other drugs known to prolong the QTc interval (fluoxetine and IV cocaine), and those known to antagonize the activity of the P450 enzymes responsible for the metabolism of LAAM and its active metabolite (fluoxetine, cocaine and marijuana). No previous reports have appeared in the literature attributing this adverse event to LAAM therapy; however, five similar cases have been reported to the manufacturer. Animal studies indicate that LAAM and metabolites prolong the action potential duration of myocardial cells. We propose that predisposed patients on high doses of LAAM may be at risk for developing TdP. Patients being treated with LAAM should receive dosages consistent with guidelines and be evaluated for concomitant diseases, interacting drug therapies, and EKG abnormalities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11760927     DOI: 10.1300/J069v20n04_02

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  22 in total

1.  Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Authors:  Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pam Sheffels; Bojan Lalovic
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Methadone-Associated QTc Prolongation: A Case Report and Review of the Literature.

Authors:  David W Abramson; Davin K Quinn; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  Pharmacological strategies for detoxification.

Authors:  Alison M Diaper; Fergus D Law; Jan K Melichar
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

4.  Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation.

Authors:  David J R Foster; Mette L Jensen; Richard N Upton; Andrew A Somogyi; Cliff Grant; Allison Martinez
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 5.  Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias.

Authors:  Michael E O'Leary; Jules C Hancox
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

6.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

Review 7.  QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.

Authors:  Alan David Kaye; Jacqueline Volpi-Abadie; J Michael Bensler; Adam M Kaye; James H Diaz
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

Review 8.  Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.

Authors:  Marek Malik
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 9.  Opioids and Cardiac Arrhythmia: A Literature Review.

Authors:  Mina Behzadi; Siyavash Joukar; Ahmad Beik
Journal:  Med Princ Pract       Date:  2018-08-02       Impact factor: 1.927

Review 10.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.